Fineline Cube

Follow:
14855 Articles
BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
CompanyDeals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS
CompanyDrug

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised
Company

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D
CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%
Company

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%

NMPA Grants Priority Review to Hengrui's Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer
CompanyDrug

NMPA Grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma
CompanyDrug

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps
CompanyDeals

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion
Company

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC
CompanyDrug

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

AbbVie Q3 Revenue Climbs 10.3% to USD 17.4 Billion as Skyrizi and Rinvoq Drive Immunology Growth; Full‑Year EPS Guidance Raised
Company

AbbVie Q3 Revenue Climbs 10.3% to USD 17.4 Billion as Skyrizi and Rinvoq Drive Immunology Growth; Full‑Year EPS Guidance Raised

AstraZeneca's Q3 Revenue Rises 7% to USD 16.21 Billion as Oncology Surges 17% and China Sales Rebound 9%
Company

AstraZeneca’s Q3 Revenue Rises 7% to USD 16.21 Billion as Oncology Surges 17% and China Sales Rebound 9%